Fig. 1From: Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumabCumulative proportion of partial responses or better (a) and complete responses (b) over time by body mass index categories. PR partial response, CR complete responseBack to article page